Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01894672
Title BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

melanoma

Therapies

Encorafenib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST